{
  "docId": "019de073-ace7-72fb-abe1-daa413db1006",
  "docSlug": "7bdf7da39a85a072a380631ad1d0379d",
  "documentTitle": "Cabaletta Bio | Investor Presentation Deck | 23 slides",
  "authorId": "cabaletta-bio",
  "authorName": "Cabaletta Bio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 23,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "Includes specific dosing details and regulatory designations (Orphan Drug, Fast Track).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-ace7-72fb-abe1-daa413db1006/18",
  "deckHref": "/decks/019de073-ace7-72fb-abe1-daa413db1006",
  "deckJsonHref": "/decks/019de073-ace7-72fb-abe1-daa413db1006.json",
  "deckAnchorHref": "/decks/019de073-ace7-72fb-abe1-daa413db1006#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.65,
        "x": 0.3,
        "y": 0.26
      },
      "kind": "diagram",
      "text": "SCREENING -> MANUFACTURING -> TREATMENT (SINGLE INFUSION) -> MONITORING (2-4 WEEKS) -> Next Patient",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5574ec20-16ce-4c37-a1e6-6e83f86c71b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.15,
        "x": 0.8,
        "y": 0.02
      },
      "kind": "image",
      "text": "Orphan Drug Designation, Fast Track Designation",
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "93743725-7ffa-4de9-ac44-592393790a87",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.04,
        "y": 0.26
      },
      "kind": "list",
      "text": "Major Inclusion Criteria: Age ≥18, MG severity Class I-IVa, MGC ≥ 4, Anti-MuSK antibody positive, Negative anti-AChR antibody test",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dcb06c58-10e7-4976-b597-56dbe8341246",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.04,
        "y": 0.51
      },
      "kind": "list",
      "text": "Major Exclusion Criteria: Prednisone > 0.25-0.5 mg/kg/day, Other autoimmune disorder requiring immunosuppressive therapies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e810c94a-5e99-40c1-bf78-be60ab9ece1c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.92,
        "x": 0.04,
        "y": 0.77
      },
      "kind": "paragraph",
      "text": "Study Endpoint & Objectives: Primary Endpoint: Adverse Events, including DLT. Secondary & Tertiary Objectives: CAART T expansion/persistence, effect on serum anti-MuSK antibody titer, use of concomitant systemic medications, effect on clinical symptoms, manufacturing success rate",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "347bfaa0-54e5-4ce9-a249-b9209e87b44b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "Open-label study to determine the maximum tolerated dose & to evaluate safety of MuSK-CAART",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "95242580-c055-4f36-be99-96669e98f41a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.65,
        "x": 0.3,
        "y": 0.35
      },
      "kind": "table",
      "text": "Part A - Dose Escalation, A - Adaptive Combination Cohorts, B - Expansion",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4db107ec-fee3-4131-8127-1a4d8d21c548",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.05,
        "y": 0.09
      },
      "kind": "title",
      "text": "Strategy for upcoming trial informed by learnings from DesCAARTes™ study",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a70e8b2a-7f90-4be6-a18e-99d1ccc32248",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "MusCAARTes™ study of MuSK-CAART",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "200fb1c9-2ad6-49a8-8eb2-4831355085c5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "ca9272ca-374a-48ee-8fa4-06bf2e64e98a",
      "evidence": "Sequential trial stages shown in arrows",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}